Targeting the androgen receptor in prostate cancer

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 10, 2014, Pages 1427-1437

  Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen receptor; Chemotherapy; Prostate cancer; Steroidogenesis

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; ARN 509; BICALUTAMIDE; CYTOCHROME P450 17; CYTOCHROME P450 17A1; DACINOSTAT; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; FULVESTRANT; GALETERONE; GELDANAMYCIN; GLUCOCORTICOID RECEPTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYFLUTAMIDE; JANUS KINASE 2; NEUTRALIZING ANTIBODY; NEW DRUG; ORTERONEL; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; ANDROGEN RECEPTOR ANTAGONIST; ANTIESTROGEN; ANTINEOPLASTIC AGENT; APALUTAMIDE; ASC J 9; CABAZITAXEL; OGX 111; PF 04928473; TANESPIMYCIN;

ANDROGEN SYNTHESIS; BINDING AFFINITY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CHEMOPROPHYLAXIS; CHROMATIN ASSEMBLY AND DISASSEMBLY; ENZYME INHIBITION; FEEDBACK SYSTEM; GENE EXPRESSION; HUMAN; MEDLINE; METASTASIS; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POINT MUTATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PUBLICATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TUMOR INVASION; ANTIANDROGEN THERAPY; CANCER CHEMOTHERAPY; CANCER PREVENTION; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; MALE; MOLECULAR PATHOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION;

ANDROGEN RECEPTOR; CHEMOTHERAPY; PROSTATE CANCER; STEROIDOGENESIS;

ANDROGEN ANTAGONISTS; ANILIDES; ANTIBODIES, NEUTRALIZING; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CURCUMIN; FLUTAMIDE; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NITRILES; OLIGONUCLEOTIDES, ANTISENSE; PHENYLTHIOHYDANTOIN; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STEROID 17-ALPHA-HYDROXYLASE; TOSYL COMPOUNDS;

EID: 84902294377     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.915313     Document Type: Review

References (81)

1. Niu Y, Chang TM, Yeh S, et al. Differential androgen receptor signalis in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene 2010;24:3593-604
2. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and ist splice variants in castration-resistant prostate cancer. Cancer Res 2012;72:3457-62
3. Veldscholte J, Berrevoets CA, Brinkmann AO, et al. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992;31:2393-9
4. Comuzzi B, Lambrinidis L, Rogatsch H, et al. The transcriptional co-activator cAMP response elemen-binding protein-binding protein is expressed in prostate cancer and enhances androgen-and anti-androgen-induced androgen receptor function. Am J Pathol 2003;162:233-41
5. Miyamoto H, Yeh S, Wilding G, Chang C. Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc Natl Acad Sci USA 1998;95:7379-84
6. Nishimura K, Ting HJ, Harada Y, Tokizane T. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res 2003;63:4888-94
7. Comuzzi B, Nemes C, Schmidt S, et al. The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. J Pathol 2004;204:159-66
8. Fenton MA, Shuster TD, Fertig AM, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin Cancer Res 1997;3:1383-8
9. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53
10. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancer treated with androgen antagonist. Cancer Res 1999;59:2511-15
11. Lee YF, Lin WJ, Huang J, et al. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells. Cancer Res 2002;62:6039-44
12. Singh RP, Agarwal R. Mechanisms of action of novel agents for prostate cancer chemoprevention. Endocr Relat Cancer 2006;13:751-8
13. Zhu W, Smith A, Young CY. A nonsteroidal anti-inflammatory drug, flufenamic acid, inhibits the expression of the androgen receptor in LNCaP cells. Endocrinology 1999;140:5451-4
14. Pan Y, Zhang JS, Gazi MH, Young CY. The cyclooxygenase 2-specific nonsteroidal anti-inflammatory drugs celecoxib and nimesulide inhibit androgen receptor activity via induction of c-Jun in prostate cancer cells. Cancer Epidemiol Biomarkers Prev 2003;12:769-74
15. Adhami VM, Malik A, Zaman N, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007;13:1611-19
16. Zhu W, Zhang JS, Young CY. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 2001;22:1399-403
17. Tsai CH, Lin FM, Yang YC, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res 2009;15:5435-44
18. Eder IE, Culig Z, Ramoner R, et al. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther 2000;7:997-1007
19. Eder IE, Hoffmann J, Rogatsch H, et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002;9:117-25
20. Eder IE, Haag P, Basik M, et al. Gene expression changes following androgen receptor elimination in LNCaP prostate cancer cells. Mol Carcinog 2003;37:181-91
21. Zhang Y, Castaneda S, Dumble M, et al. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer. Mol Cancer Ther 2011;10:2309-19
22. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res 2002;62:1008-13
23. Heemers HV, Sebo TJ, Debes JD, et al. Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Res 2007;67:3422-30
24. Santer FR, Hoschele PP, Oh SJ, et al. Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Mol Cancer Ther 2011;10:1644-55
25. Ianculescu I, Wu DY, Siegmund KD, Stallcup MR. Selective roles of cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J Biol Chem 2012;287:4000-13
26. Agoulnik IU, Vaid A, Bingman WE III, et al. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005;65:7959-67
27. Wang Y, Lonard DM, Yu Y, et al. Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Mol Endocrinol 2011;25:2041-53
28. Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer developemnt and metastasis. Am J Pathol 2004;164:2003-12
29. Leung YK, Mak P, Hassan S. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 2006;103:13162-7
30. Bhattacharyya RS, Krishnan AV, Swami S, Feldman D. Fulvestrant (ICI 182, 780 down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Mol Cancer Ther 2006;5:1539-49
31. Fernandes SA, Gomes GR, Siu ER, et al. The anti-oestrogen fulvestrant (ICI 182, 780) reduces the androgen receptor expression, ERK phosphorylation and cell proliferation in the rat ventral prostate. Int J Androl 2011;34:486-500
32. Bektic J, Berger AP, Pfeil K, et al. Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol 2004;45:245-51
33. Wetherill YB, Hess-Wilson JK, Comstock CE, et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther 2006;5:3181-90
34. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-71
35. Attard G, Reid AH, ÁHern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-8
36. Danila DC, Anand A, Sung CC, et al. TMPRSS-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011;60:897-904
37. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-25
38. Zengerling F, Streicher W, Schrader AJ, et al. Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells. Int J Mol Sci 2012;13:11530-42
39. Richards J, Lim AC, Hay CW, et al. Interactions of abiraterone, eplenerone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012;72:2176-82
40. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138-48
41. Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomized phase 3 trial. Lancet Oncol 2013;14:1193-9
42. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82
43. Saprita AJ, Wang Z. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007;67:509-20
44. ÓMalley KJ, Langmann G, Ai J, et al. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance. Prostate 2012;72:1117-23
45. Lamoureux F, Thomas C, Yin MJ, et al. A novel HSP90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis. Clin Cancer Res 2011;17:2301-13
46. Lamoureux F, Thomas C, Yin MJ, et al. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer. Cancer Res 2011;71:5838-49
47. Chen L, Meng S, Wang H, et al. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 2005;4:1311-19
48. Huang WC, Havel JJ, Zhau HE, et al. Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells. Clin Cancer Res 2008;14:5341-7
49. Huang WC, Zhau HE, Chung LW. Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells. J Biol Chem 2010;285:7947-56
50. Haddad BR, Gu L, Mirtti T, et al. STAT5A/B gene locus undergoes amplification during human prostate cancer progression. Am J Pathol 2013;182:2264-75
51. Thomas C, Zoubeidi A, Kuruma H, et al. Transcription factor Stat5 knockdown enhances androgen receptor degradation and delays castration-resistant prostate cancer progression in vivo. Mol Cancer Ther 2011;10:347-59
52. Nadiminty N, Tummala R, Lou W, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem 2012;287:1527-37
53. Yamashita S, Lai KP, Chuang KL, et al. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors. Neoplasia 2012;14:74-83
54. Lai KP, Huang CK, Chang YJ, et al. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells. Am J Pathol 2013;182:460-73
55. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009;69:8386-94
56. Zhu ML, Horbinski CM, Garzotto M, et al. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 2010;70:7992-8002
57. Thadani-Mulero M, Portella L, Sun S, et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res 2014;74(8):2270-82
58. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90
59. Jia S, Gao X, Lee SH, et al. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discov 2013;3:44-51
60. Scher H, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375:1437-46
61. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187-97
62. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30-6
63. Belikov S, Oberg C, Jaaskelainen T, et al. FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide). Mol Cell Endocrinol 2013;365:95-107
64. Li Y, Chan SC, Brand LJ, et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistance prostate cancer cell lines. Cancer Res 2013;73:483-9
65. Kuruma H, Matsumoto H, Shiota M, et al. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV 3100-resistant prostate cancer growth in vitro and in vivo. Mol Cancer Ther 2013;12:567-76
66. Lin TH, Lee SO, Niu Y, et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® lead to promotion versus suppression of prostate cancer metastasis. J Biol Chem 2013;288:19359-69
67. Nadiminty N, Tummala R, Liu C, et al. NF kappa B/p52 induces resistance to enzalutamide in prostate cancer: role of androgen receptor and its variants. Mol Cancer Ther 2013;12:1629-37
68. Lin TH, Izumi K, Lee SO, et al. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastatsis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling. Cell Death Dis 2013;4:764
69. Liu C, Zhu Y, Lou W, et al. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate 2014;74:201-9
70. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enalutamide and ARN-509. Cancer Discov 2013;3:1020-9
71. Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov 2013;3:1030-43
72. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013;155:1309-22
73. Hara T, Kouno J, Kaku T, et al. Effect of a novel 17, 20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. J Steroid Biochem Mol Biol 2013;134:80-91
74. Drecier R, Maclean D, Suri A, et al. Phase I/II trial of orteronel (TAK-700)-an investigational 17, 20-lyase inhibitor in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2014;20(5):1335-44
75. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012;72:1494-503
76. Soifer HS, Souleimanian N, Wu S, et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem 2012;287:3777-87
77. Andersen RJ, Mawji NR, Wang J, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 2010;17:535-46
78. Wang Y, Kreisberg JI, Ghosh PM. Cross-talk between the androgen receptor and the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer. Curr Cancer Drug Targets 2007;7:591-604
79. Carver BS, Chapinski C, Wongvipat J, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011;19:575-86
80. Thomas C, Lamoureux F, Crafter C, et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-reesistant prostate cancer progression in vivo. Mol Cancer Ther 2013;12:2342-5
81. Mediwala SN, Sun H, Szafran AT, et al. The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. Prostate 2013;73:267-77